Positron emission tomography evaluation of dopaminergic pathways

J. S. Perlmutter; C. A. Tamminga

doi:10.1097/00002826-199501001-00020

Positron emission tomography evaluation of dopaminergic pathways

J. S. Perlmutter, C. A. Tamminga

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D₂-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.

Original language	English
Pages (from-to)	S188-S194
Journal	Clinical Neuropharmacology
Volume	18
Issue number	SUPPL. 1
DOIs	https://doi.org/10.1097/00002826-199501001-00020
State	Published - Jan 1 1995

Keywords

Dopamine
Parkinson's disease
Positron emission tomography
Receptors
Transmitters

Access to Document

10.1097/00002826-199501001-00020

Cite this

@article{aa3f115e49674b759ae3205c921e641c,

title = "Positron emission tomography evaluation of dopaminergic pathways",

abstract = "Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.",

keywords = "Dopamine, Parkinson's disease, Positron emission tomography, Receptors, Transmitters",

author = "Perlmutter, {J. S.} and Tamminga, {C. A.}",

year = "1995",

month = jan,

day = "1",

doi = "10.1097/00002826-199501001-00020",

language = "English",

volume = "18",

pages = "S188--S194",

journal = "Clinical Neuropharmacology",

issn = "0362-5664",

number = "SUPPL. 1",

}

TY - JOUR

T1 - Positron emission tomography evaluation of dopaminergic pathways

AU - Perlmutter, J. S.

AU - Tamminga, C. A.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.

AB - Positron emission tomography (PET) studies of dopamine receptors have provided exciting new insights into basal ganglia function that are particularly relevant to Parkinson's disease. Previous studies have concentrated on alterations in radioligand binding of primarily D2-like dopaminergic binding sites. Development of new radioligands with greater dopamine subtype specificity promises to reveal additional information about dopaminergic function. Also, pharmacological activation techniques with PET may permit identification of alterations in receptor-mediated pathways not associated with direct changes in receptors.

KW - Dopamine

KW - Parkinson's disease

KW - Positron emission tomography

KW - Receptors

KW - Transmitters

UR - http://www.scopus.com/inward/record.url?scp=0029058150&partnerID=8YFLogxK

U2 - 10.1097/00002826-199501001-00020

DO - 10.1097/00002826-199501001-00020

M3 - Article

AN - SCOPUS:0029058150

SN - 0362-5664

VL - 18

SP - S188-S194

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

IS - SUPPL. 1

ER -

Positron emission tomography evaluation of dopaminergic pathways

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this